Michael Gross – Startup Investor Profile

Michael Gross is a Managing Director at Beringea specializing in healthcare, technology-enabled services, and sustainability. His investment focus areas include healthcare, technology-enabled services, and sustainability. He has a track record in leading M&A transactions and capital raises. Michael’s previous investments include Delphinus Medical Technologies, Genomenon, and Freeosk Inc. He typically invests in Series A and later stages with check sizes ranging from millions of dollars. Michael engages in board memberships and observer roles, showing a hands-on partnership and collaboration style.

Location: Farmington Hills, Michigan

Country: United States of America

Investment Regions:

Investment Stages: pre-seed, seed

Website: https://www.beringea.com/

AI Reasoning: Searches found Michael Gross at Beringea with past investments such as Delphinus (2010), Genomenon (Series B reported around 2022), and Freeosk (Series A around 2013). The most recent verifiable investment activity linked to Beringea and Michael Gross appears to be Genomenon reported in 2022, which is more than 12 months prior to the reference date, indicating inactivity over 12 months. Thus classify as low-active.

Low Activity – Only known angel investments more than 12 months ago.

Active – Known angel investments between the last 12 and 6 months.

Very Active – Known angel investments in the last 6 months.